MANNKIND CORP

Explore MannKind Corp’s biopharma journey: diabetes & cancer therapies, volatile Nasdaq stock, $1.26B cap, and future growth prospects.

Discover MannKind Corp’s $1.4B biotech journey: from diabetes breakthroughs to market highs and lows, navigating R&D risks while pushing innovative therapies.

Explore why MannKind’s stock fell from a $6.51 peak to $4.52, the challenges its biotech pipeline faces, and what investors need to watch for future growth.

FDA approves Afrezza inhaled insulin for kids – MannKind’s breakthrough offers teens a quick, injection‑free diabetes option, boosting control and adherence.

Discover how MannKind Corporation’s 15% revenue surge and partnership with United Therapeutics fuel its growth, expanding inhalation therapies for pulmonary hypertension and beyond.

Explore MannKind Corp’s biotech journey: high‑growth P/E, volatile Nasdaq price, and innovative therapies for diabetes, cancer, and autoimmune conditions.

Read how MannKind Corp’s upcoming ATTD 2026 data could ignite Afrezza’s future, boost investor confidence, and reshape the inhaled insulin market.

Explore MannKind’s biotech journey—high P/E optimism, volatile stock, and conference insights on its innovative diabetes, cancer, and autoimmune therapies.

Explore MannKind’s biopharma strategy, stock performance, and innovation pipeline in diabetes, cancer, and autoimmune therapy markets.

New pediatric trial for MannKind’s inhaled insulin Afrezza targets kids with type‑1 diabetes, boosting the biopharma firm’s diabetes pipeline and market potential.